There was disappointment, however, in a second phase 2 study in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), which missed its primary endpoint and will be discontinued. SSc-ILD is a chronic autoimmune disease that leads to inflammation and scarring (fibrosis) in the lungs. TL1A has become a hot topic in immunology and inflammation R&D, with tulisokibart slightly ahead of rival candidates like Teva/Sanofi's duvakitug and Roche's afimkibart, which are also in the final stages of clinical testing. A one-time $5.7 billion charge related to the just-completed $6.7 billion takeover of Terns Pharma and its oral BCR-ABL inhibitor for leukaemia, MK-4208 (formerly TERN-701), tipped MSD into a loss for the quarter. The company has raised its 2026 revenue forecast to $66.3 to $67.3 billion, from a previous range of $65.8 to $67.0 billion, on the back of the second-quarter performance.